HMGB1 and leiomyosarcoma: The combination leverages ICD induced by doxorubicin (HMGB1/ATP release) and synergizing with nivolumab’s PD-1 blockade to enhance T cell activation and overcome tumor immune evasion in advanced leiomyosarcoma, indicating that ICD–ICI synergy may enhance T cell activation and reduce immune escape [50].